The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials

Journal of Association of Physicians of India

Volumn 60, Issue 8, 2012, Pages 28-30

  Trivedi, Mayur ^a   Patel, Vipul ^b   Soman, Rajeev ^b   Rodriguez, Camilla ^a   Singhal, Tanu ^c  

^a P D HINDUJA NATIONAL HOSPITAL   (India)

^b Dept of Internal Medicine ^*  (India)

^c Kokilaben Dhirubhai   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAM; BETA LACTAMASE; CARBAPENEM DERIVATIVE;

ADULT; ARTICLE; BIOSYNTHESIS; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; ENZYMOLOGY; FEMALE; HUMAN; INDIA; ISOLATION AND PURIFICATION; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; TERTIARY HEALTH CARE; TREATMENT OUTCOME;

ADULT; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BETA-LACTAMS; CARBAPENEMS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; INDIA; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROSPECTIVE STUDIES; TERTIARY HEALTHCARE; TREATMENT OUTCOME;

EID: 84865194918     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Menon T, Bindu D, Kumar C P G, S Nalini, Thirunarayan M A. Comparison of double disc and three dimensional methods to screen for ESBL producers in a tertiary care hospital. Indian Journal of Medical Microbiology 2006;24:117-120.
2. Michael A, Pfaller, Segreti J. Overview of the epidemiological profile and laboratory detection of Extended-spectrum Beta lactamases. Clinical Infectious Diseases 2006;42:S153-63.
3. Garner J S, Emori W R, Horan T C, Hughes J M. CDC definitions for Nosocomial infections. American Journal of Infection Control 1988;16:128-40.
4. Akpunonu B, Michaelis J, Uy CN, Tennenburg A M. Multicenter postmarketing assessment of levofloxacin in the treatment of adults with community acquired pneumonia. Clinical Infectious Diseases 2004;38(supplement1):S5-15.
5. Ensor V M, Shahid M, Evans J T, Hawkey P M. Occurrence, prevalence and genetic environment of CTX-M Beta-lactamases in Enterobacteriaceae from Indian Hospitals. Journal of Antimicrobial Chemotherapy 2006;58:1260-1263.
6. Mathai D, Rhomberg P, Bidenbach D J, Jones R N. The India Antimicrobial Resistance Study Group. Evaluation of the in-vitro activity of six broad spectrum beta-lactum antimicrobial agents tested against recent clinical isolates from India: a survey of ten medical center laboratories. 2002;44:367-377.
7. Chaudhari BN, Rodrigues C, Balaji V, Iyer R, Sekar U, Wattal C, Chitnis DS, Dhole TN, Joshi S. Incidence of ESBL producers amongst Gram negative bacilli isolated from Intra-abdominal infections across India (Based on the Smart Study, 2007 Data) Poster GN 103 presented at ISAAR 2009.
8. Du B, Long Y, Liu H, Chen D, Liu D, Xu Y, Xie X. Intensive Care Medicine 2002;28:1718-23.
9. Paterson D L. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum p-lactamases (ESBLs). Clinical Microbiology and Infections 2000;6:460-463.
10. Rajwadkar-More V, Soman R, Purandare B, Dastur F, Rodrigues C. A clinicomicrobiological study on carbapenem resistance at a tertiary care hospital. Poster GN 110 presented at ISAAR 2009.
11. Payal Deshpande, Camilla Rodrigues, Anjali Shetty, Farhad Kapadia, Ashit Hedge, Rajeev Soman. New Delhi Metallo-b lactamases (NDM-1) in Enterobacteriaceae:Treatment options with Carbapenems compromised. JAPI 2010;58:147-149.
12. Abdul Ghafur K. An obituary-On the death of Antibiotics! Editorial. JAPI 2010;58:143-144